AL001, also known by its generic name latozinemab, is a proprietary monoclonal antibody developed by Alector Inc. that represents a novel therapeutic approach for neurodegenerative diseases characterized by progranulin deficiency[@alector]. This antibody targets the sortilin receptor (SORT1), a critical clearance receptor that regulates progranulin levels in the brain and periphery[@carlo2012]. By blocking sortilin-mediated uptake and degradation of progranulin, AL001 increases progranulin concentrations in the cerebrospinal fluid (CSF) and brain tissue, potentially providing neuroprotective effects in conditions such as frontotemporal dementia (FTD) with GRN mutations and Alzheimer's disease[@patel2022].
The development of AL001 represents a landmark in precision medicine for neurodegenerative diseases, as it targets a specific molecular mechanism—the progranulin deficiency resulting from GRN gene mutations—that accounts for approximately 5-10% of familial FTD cases[@rascovsky2024]. Unlike symptomatic treatments, AL001 aims to address the underlying cause of progranulin haploinsufficiency, potentially slowing or preventing disease progression in affected individuals.
AL001, also known by its generic name latozinemab, is a proprietary monoclonal antibody developed by Alector Inc. that represents a novel therapeutic approach for neurodegenerative diseases characterized by progranulin deficiency[@alector]. This antibody targets the sortilin receptor (SORT1), a critical clearance receptor that regulates progranulin levels in the brain and periphery[@carlo2012]. By blocking sortilin-mediated uptake and degradation of progranulin, AL001 increases progranulin concentrations in the cerebrospinal fluid (CSF) and brain tissue, potentially providing neuroprotective effects in conditions such as frontotemporal dementia (FTD) with GRN mutations and Alzheimer's disease[@patel2022].
The development of AL001 represents a landmark in precision medicine for neurodegenerative diseases, as it targets a specific molecular mechanism—the progranulin deficiency resulting from GRN gene mutations—that accounts for approximately 5-10% of familial FTD cases[@rascovsky2024]. Unlike symptomatic treatments, AL001 aims to address the underlying cause of progranulin haploinsufficiency, potentially slowing or preventing disease progression in affected individuals.
AL001 is a fully human IgG1 monoclonal antibody designed to bind with high affinity to sortilin, a member of the Vps10p-domain receptor family that functions as a major clearance receptor for progranulin in the central nervous system["@nykjaer2010"]. Progranulin (encoded by the GRN gene) is a secreted glycoprotein with diverse biological functions including lysosomal function regulation, immune response modulation, and neuroprotection["@petkau2023"]. Loss-of-function mutations in GRN cause haploinsufficiency, leading to reduced progranulin levels and resulting in FTD, also known as FTD-GRN["@ghidoni2023"].
The therapeutic rationale for AL001 stems from the observation that heterozygous GRN mutation carriers have approximately 50% reduced plasma and CSF progranulin levels, which correlates with disease onset and progression["@sleiman2017"]. By inhibiting sortilin-mediated progranulin clearance, AL001 can restore progranulin levels toward normal, potentially providing therapeutic benefit not only for FTD-GRN patients but also for sporadic FTD and Alzheimer's disease where progranulin levels may be reduced["@arrant2023"].
Sortilin (SORT1) is a type I transmembrane receptor expressed abundantly in neurons and glia throughout the brain and in peripheral tissues including liver and kidney[@hermansson2023]. It functions as a multi-ligand receptor involved in various physiological processes, including lipoprotein metabolism, neurotrophin signaling, and importantly, progranulin clearance[@yang2022]. Studies have demonstrated that sortilin binds progranulin with high affinity and internalizes it for lysosomal degradation, making it the primary pathway for progranulin catabolism in the brain[@gustafson2024].
Research published in Nature Neuroscience showed that genetic deletion of sortilin in mice results in a 5-6 fold increase in plasma progranulin levels, confirming its essential role in progranulin homeostasis[@jiang2022]. Conversely, overexpression of sortilin leads to reduced progranulin levels. This bidirectional relationship makes sortilin an attractive therapeutic target for conditions where progranulin levels are deficient.
Progranulin is a 593-amino acid secreted glycoprotein that undergoes proteolytic processing to generate smaller granulin peptides[@bateman2023]. Both progranulin and its cleavage products (granulins) have been implicated in various biological functions:
AL001 binds to the extracellular domain of sortilin with picomolar affinity, effectively blocking progranulin binding and internalization[@alector2023]. Upon binding, AL001 triggers internalization of the AL001-sortilin complex, but this complex is recycled back to the cell surface rather than being targeted for lysosomal degradation. This recycling mechanism allows for sustained blockade of progranulin clearance with intermittent dosing.
Pharmacodynamic studies in non-human primates demonstrated that AL001 administration resulted in dose-dependent increases in CSF progranulin levels of up to 2-3 fold above baseline[@boxer2023]. Importantly, these elevated levels were maintained throughout the dosing interval and returned to baseline after treatment cessation, indicating reversible pharmacology.
The first-in-human study of AL001 (NCT02942589) was a randomized, placebo-controlled trial in healthy volunteers that evaluated single ascending doses and multiple ascending doses[@alectora]. The study demonstrated:
The INFRONT program comprises multiple Phase 2 studies evaluating AL001 in FTD-GRN patients:
INFRONT-2 is an open-label study evaluating the long-term safety and pharmacodynamics of AL001 in FTD-GRN patients[@infront]. Key findings include:
INFRONT-3 is a randomized, placebo-controlled Phase 2/3 trial evaluating AL001 in FTD-GRN patients[@infronta]. The study enrolled patients with heterozygous GRN mutations and clinical symptoms of FTD. Primary endpoints include:
Given the role of progranulin in AD pathophysiology, Alector has also conducted Phase 1b studies evaluating AL001 in patients with mild-to-moderate Alzheimer's disease (NCT04638842)[@alzheimers]. These studies demonstrated:
AL001 represents a first-in-class therapeutic approach for progranulin deficiency. Other approaches being developed include:
| Agent | Company | Mechanism | Development Stage |
|-------|---------|-----------|-------------------|
| AL001 (Latozinemab) | Alector | Anti-sortilin antibody | Phase 3 |
| PRN-224 | Prothelia | Progranulin replacement (AAV) | Preclinical |
| Atacarbotug | Eli Lilly | Anti-Aβ antibody | Phase 3 (terminated) |
| Semorinemab | Roche/Genentech | Anti-tau antibody | Phase 2 |
The progranulin-elevating approach is unique in that it targets the upstream cause of progranulin haploinsufficiency rather than downstream disease manifestations. This mechanism may provide advantages in terms of disease modification potential.
FTD-GRN patients are identified through genetic testing for heterozygous loss-of-function mutations in the GRN gene. Over 100 pathogenic GRN mutations have been identified, including nonsense, frameshift, and splice-site mutations that result in reduced or absent progranulin expression[@gijselinck2024].
Several biomarkers are used to monitor AL001 treatment response:
Based on clinical trial data to date, AL001 has demonstrated an acceptable safety profile:
While initially developed for FTD-GRN, the progranulin-elevating mechanism may benefit other FTD subtypes and related conditions. Studies are planned to evaluate AL001 in:
Future development may explore combination therapies that pair progranulin elevation with other disease-modifying approaches:
Refinement of patient selection using progranulin levels, neurofilament markers, and imaging biomarkers may improve treatment response and enable earlier intervention in pre-symptomatic GRN mutation carriers.
AL001 (latozinemab) represents a novel, first-in-class therapeutic approach for neurodegenerative diseases characterized by progranulin deficiency. By targeting sortilin-mediated progranulin clearance, AL001 increases brain progranulin levels and may provide disease-modifying effects in FTD-GRN and potentially Alzheimer's disease. The positive results from INFRONT-3 mark an important milestone in the development of precision medicine approaches for neurodegenerative diseases.
The development of AL001 began with the identification of sortilin as the primary clearance receptor for progranulin[^26]. Alector researchers screened a library of antibodies against sortilin and identified several candidates with high binding affinity and ability to block progranulin uptake. AL001 was selected based on its favorable properties including high affinity, excellent selectivity, and suitable developability characteristics for clinical development[^27].
Preclinical evaluation of AL001 included studies in non-human primates (cynomolgus monkeys) that demonstrated:
Additional preclinical studies provided mechanistic insights into the therapeutic potential of progranulin elevation:
Frontotemporal dementia is a heterogeneous group of neurodegenerative disorders characterized by progressive deterioration of behavior, personality, and language function. FTD is the second most common cause of early-onset dementia after Alzheimer's disease, with an estimated prevalence of 15-20 per 100,000 individuals aged 45-64 years[^32].
FTD-GRN, also known as familial FTD due to GRN mutations, accounts for approximately 5-10% of all FTD cases and represents one of the most common genetic forms of FTD[^33]. Key features include:
While progranulin deficiency is most strongly associated with FTD, several lines of evidence suggest it may also contribute to Alzheimer's disease pathology[^34]:
The clinical development program for AL001 has focused on patients with:
Key clinical endpoints in the INFRONT studies include:
A key aspect of the AL001 development program is the extensive biomarker characterization:
AL001 (latozinemab) has received:
The development of AL001 for FTD-GRN represents a significant investment in precision medicine for rare neurodegenerative diseases. Considerations include:
AL001 (latozinemab) represents a novel, first-in-class therapeutic approach for neurodegenerative diseases characterized by progranulin deficiency. By targeting sortilin-mediated progranulin clearance, AL001 increases brain progranulin levels and may provide disease-modifying effects in FTD-GRN and potentially Alzheimer's disease. The positive results from INFRONT-3 mark an important milestone in the development of precision medicine approaches for neurodegenerative diseases.
The success of AL001 validates the progranulin-elevating approach and supports further development of similar strategies for related neurodegenerative conditions. As the field moves toward molecularly targeted therapies, AL001 stands as an example of translating genetic insights into clinically meaningful treatments.